|1.||Teillac, Pierre: 5 articles (08/2005 - 05/2002)|
|2.||Vela-Navarrete, Remigio: 5 articles (02/2005 - 05/2002)|
|3.||Ito, Yoshihiko: 4 articles (01/2014 - 03/2009)|
|4.||Yamada, Shizuo: 4 articles (01/2014 - 03/2009)|
|5.||Boyle, Peter: 4 articles (06/2004 - 05/2002)|
|6.||Gillenwater, Jay G: 4 articles (06/2004 - 05/2002)|
|7.||Perrin, Paul: 4 articles (06/2004 - 05/2002)|
|8.||Debruyne, Frans: 4 articles (06/2004 - 05/2002)|
|9.||Raynaud, Jean-Pierre: 4 articles (06/2004 - 05/2002)|
|10.||Hamdy, Freddie C: 4 articles (06/2004 - 05/2002)|
|1.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
01/01/2002 - "Thus, continuous 5-year therapy with lipidosterol extract Serenoa repens (permixon) proved highly effective and safe in 26 patients with initial or moderate symptoms of prostatic hyperplasia."
03/01/2009 - "Saw palmetto extract (SPE), an extract from the ripe berries of the American dwarf palm, has been widely used as a therapeutic remedy for urinary dysfunction due to benign prostatic hyperplasia (BPH) in Europe. "
11/01/2002 - "Permixon, the lipidosterolic extract of Serenoa repens, is widely used for the treatment of symptoms associated with benign prostatic hyperplasia (BPH). "
04/01/2004 - "To determine, by analysing all available clinical trial data, the clinical efficacy against placebo of an extract from the fruit of the American dwarf palm tree, Serenoa repens (Permixon, Pierre Fabre Médicament, Castres, France), as there is controversy about the use of phytotherapeutic agents in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). "
02/09/2006 - "In this double-blind trial, we randomly assigned 225 men over the age of 49 years who had moderate-to-severe symptoms of benign prostatic hyperplasia to one year of treatment with saw palmetto extract (160 mg twice a day) or placebo. "
04/01/2004 - "This meta-analysis of all available published trials of Permixon for treating men with BPH showed a significant improvement in peak flow rate and reduction in nocturia above placebo, and a 5-point reduction in the IPSS."
04/01/2004 - "There was some heterogeneity among the studies for nocturia; one over 2 years involving 396 patients and showing no difference between placebo and Permixon had a large effect on the results. "
04/01/2000 - "This meta-analysis of all available published trials of Permixon in the treatment of men with benign prostatic hyperplasia revealed a significant improvement in peak flow rate and reduction in nocturia greater than with placebo."
02/01/1993 - "In a multicentre study in four urological departments in the Czech Republic the authors evaluated, based on an elaborated protocol, the effect of the preparation Permixon in patients with complaints associated with benign hyperplasia of the prostate (BPH). "
04/01/2002 - "The Serenoa repens lipido-sterolic extract (SRLSE, Permixon, Pierre Fabre Medicament, Castres, France) is used to treat benign prostate hyperplasia. "
01/01/1984 - "Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate."
10/01/1996 - "Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients."
04/01/2000 - "Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride."
06/01/2012 - "The objective of this study was to evaluate the efficacy of an extract of Serenoa repens (Permixon) in the treatment of lower urinary tract symptoms (LUTS) in patients with chronic benign prostate diseases with associated inflammation, also taking into consideration the influence of treatment on sexual function and, therefore, on patients' quality of life. "
09/01/2004 - "Permixon-treated patients demonstrated inhibition of prostatic epithelium proliferative activity by 32% (p = 0.0001) and a rise in the stage of proliferative centers development from stage II-III to IV-V. Intensity of inflammation in prostatic tissue decreased by 53% in the study group and insignificantly in the control group. "
06/01/2012 - "Permixon combination with an alpha-blocker is associated with benefits in terms of speed of onset of action, reduction of inflammation, and a positive benefit regarding sexual problems when compared with use of alpha-blocker monotherapy. "
09/01/2004 - "Thus, permixon treatment of BPH leads to a significant rise in stromal-parenchymatous correlation due to inhibition of proliferative activity of prostatic epithelium and attenuation of inflammation."
11/01/2003 - "BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. "
|2.||Androgen Receptors (Androgen Receptor)
|1.||Transurethral Resection of Prostate (TURP)
|2.||Phytotherapy (Herbal Therapy)